111 (YI) Status Update summary
Event summary combining transcript, slides, and related documents.
Status Update summary
17 Jan, 2026Key challenges in China's pharmaceutical supply chain
Market fragmentation with thousands of companies and distributors limits scale and efficiency.
Lack of digitization and transparency creates friction and inefficiencies.
Limited supply chain optimization leads to excess stock and high stock-out rates.
Technology and operational solutions
Over 30 proprietary systems developed for supply chain management, including demand forecasting and price intelligence.
Innovations have reduced procurement costs from over 5% to 2.6% of revenue in five years.
Digital tools extend to partners, providing visibility and optimization for both upstream and downstream stakeholders.
Fulfillment network scale and models
Operates 13 fulfillment centers, including five super hubs in major cities, covering all of China.
Uses a mix of self-built, partner-transformed, and franchise models, all with standardized systems and quality control.
New fulfillment centers reduce setup time by 70% through partnerships.
Latest events from 111
- Revenue fell 33.1% year-over-year, but marketplace and promotional product growth offset losses.YI
Q1 2026 - Asset-light transition drove margin gains and operating profitability despite lower revenues.YI
Q4 2025 - Asset-light transition delivers operational profitability and cash flow amid revenue decline.YI
Q3 2025 - Sustained profitability, digital innovation, and demographic trends drive optimism despite challenges.YI
Fireside Chat - Operational profitability and improved margins achieved despite revenue decline and industry headwinds.YI
Q3 2024 - Profitability, expansion, and digital innovation drive strong outlook amid favorable policy shifts.YI
Fireside Chat with Water Tower Research - Operational profitability sustained, efficiency and digitalization drive growth amid flat revenue.YI
Q2 2024 - Operational profit, positive cash flow achieved; AI and network expansion to drive 2025 growth.YI
Status Update - First-ever annual operating profit and positive cash flow achieved amid revenue decline.YI
Q4 2024